|
TW333456B
(en)
*
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
|
US6087324A
(en)
*
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
NO942396L
(no)
*
|
1993-06-24 |
1994-12-27 |
Takeda Chemical Industries Ltd |
Preparat med vedvarende frigiving av anti-endotelin substans
|
|
DE4342091A1
(de)
*
|
1993-12-09 |
1995-06-14 |
Asta Medica Ag |
Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
|
|
AU4459196A
(en)
*
|
1995-01-23 |
1996-08-14 |
Takeda Chemical Industries Ltd. |
Sustained-release preparation and use
|
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
|
TW448055B
(en)
*
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
|
US6143037A
(en)
*
|
1996-06-12 |
2000-11-07 |
The Regents Of The University Of Michigan |
Compositions and methods for coating medical devices
|
|
US5932547A
(en)
|
1996-07-03 |
1999-08-03 |
Alza Corporation |
Non-aqueous polar aprotic peptide formulations
|
|
US5916582A
(en)
*
|
1996-07-03 |
1999-06-29 |
Alza Corporation |
Aqueous formulations of peptides
|
|
US5981489A
(en)
*
|
1996-07-18 |
1999-11-09 |
Alza Corporation |
Non-aqueous protic peptide formulations
|
|
PT839525E
(pt)
*
|
1996-10-31 |
2004-10-29 |
Takeda Chemical Industries Ltd |
Preparacao de libertacao prolongada
|
|
US5968895A
(en)
*
|
1996-12-11 |
1999-10-19 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
|
US6126919A
(en)
*
|
1997-02-07 |
2000-10-03 |
3M Innovative Properties Company |
Biocompatible compounds for pharmaceutical drug delivery systems
|
|
US5945126A
(en)
*
|
1997-02-13 |
1999-08-31 |
Oakwood Laboratories L.L.C. |
Continuous microsphere process
|
|
US6030975A
(en)
*
|
1997-03-14 |
2000-02-29 |
Basf Aktiengesellschaft |
Carboxylic acid derivatives, their preparation and use in treating cancer
|
|
US6143314A
(en)
*
|
1998-10-28 |
2000-11-07 |
Atrix Laboratories, Inc. |
Controlled release liquid delivery compositions with low initial drug burst
|
|
US6270802B1
(en)
|
1998-10-28 |
2001-08-07 |
Oakwood Laboratories L.L.C. |
Method and apparatus for formulating microspheres and microcapsules
|
|
PT1158014E
(pt)
|
1998-12-15 |
2005-04-29 |
Takeda Pharmaceutical |
Processo para a producao de poliesteres biodegradaveis
|
|
DE10008880A1
(de)
*
|
1999-02-19 |
2000-08-24 |
Bioserv Ag |
Bioabbaubare Komposite zur Herstellung von Mikrokapseln
|
|
US7358330B2
(en)
*
|
2001-03-29 |
2008-04-15 |
Biotempt B.V. |
Immunoregulatory compositions
|
|
AU2001264264A1
(en)
*
|
2000-06-14 |
2001-12-24 |
Takeda Chemical Industries Ltd. |
Sustained release compositions
|
|
US20030176360A1
(en)
|
2000-07-05 |
2003-09-18 |
Yasutaka Igari |
Medicinal preparations for treating sex hormone-dependent diseases
|
|
DE60118575T3
(de)
*
|
2000-08-07 |
2011-05-19 |
Takeda Pharmaceutical Co. Ltd. |
Milchsäurepolymer und verfahren zu dessen herstellung
|
|
US7090869B2
(en)
|
2000-12-01 |
2006-08-15 |
Takeda Pharmaceutical Company Limited |
Method for producing preparation containing bioactive substance
|
|
WO2002058672A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Debio Recherche Pharmaceutique S.A. |
Microparticles of biodegradable polymer encapsulating a biologically active substance
|
|
WO2002058671A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Debio Recherche Pharmaceutique S.A. |
Burst free pharmaceutical microparticules
|
|
CA2451187C
(en)
|
2001-06-22 |
2012-08-14 |
Southern Biosystems, Inc. |
Zero-order prolonged release coaxial implants
|
|
TWI225416B
(en)
|
2001-06-29 |
2004-12-21 |
Takeda Chemical Industries Ltd |
Sustained-release composition and process for producing the same
|
|
AU2002343681B2
(en)
|
2001-11-12 |
2006-07-06 |
Alkermes Controlled Therapeutics, Inc. |
Biocompatible polymer blends and uses thereof
|
|
CA2466659A1
(en)
|
2001-11-13 |
2003-05-22 |
Takeda Chemical Industries, Ltd. |
Anticancer agents
|
|
JP2006514914A
(ja)
*
|
2002-02-14 |
2006-05-18 |
バイエル・フアーマシユーチカルズ・コーポレーシヨン |
有機溶媒中および乾燥状態のペプチドの安定化における製剤の戦略
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
|
EP1866319B1
(en)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
|
DE602006000381T2
(de)
*
|
2005-04-28 |
2008-12-18 |
Nipro Corp., Osaka |
Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer
|
|
US8329207B2
(en)
|
2005-05-23 |
2012-12-11 |
Natural Alternatives International, Inc. |
Compositions and methods for the sustained release of beta-alanine
|
|
TWI364292B
(en)
*
|
2005-06-30 |
2012-05-21 |
Ipsen Pharma Sas |
Glp-1 pharmaceutical compositions
|
|
US7942867B2
(en)
*
|
2005-11-09 |
2011-05-17 |
The Invention Science Fund I, Llc |
Remotely controlled substance delivery device
|
|
EP2918283B1
(en)
|
2005-12-30 |
2018-01-31 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Extended release of neuregulin for improved cardiac function
|
|
WO2007106494A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Methods and compositions for treatment of diastolic heart failure
|
|
AU2007225207A1
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Formulations of sitaxsentan sodium
|
|
US8063221B2
(en)
*
|
2006-03-13 |
2011-11-22 |
Kyorin Pharmaceutical Co., Ltd. |
Aminoquinolones as GSK-3 inhibitors
|
|
US20090258028A1
(en)
*
|
2006-06-05 |
2009-10-15 |
Abbott Cardiovascular Systems Inc. |
Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug
|
|
US8323676B2
(en)
*
|
2008-06-30 |
2012-12-04 |
Abbott Cardiovascular Systems Inc. |
Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug
|
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
|
US8017237B2
(en)
|
2006-06-23 |
2011-09-13 |
Abbott Cardiovascular Systems, Inc. |
Nanoshells on polymers
|
|
DK2049081T3
(da)
|
2006-08-09 |
2013-02-25 |
Intarcia Therapeutics Inc |
Osmotiske leveringssystemer og stempelarrangementer
|
|
AU2007297597B2
(en)
|
2006-09-21 |
2013-02-21 |
Kyorin Pharmaceuticals Co., Ltd. |
Serine hydrolase inhibitors
|
|
CN101687788A
(zh)
|
2006-10-19 |
2010-03-31 |
奥斯拜客斯制药有限公司 |
取代的吲哚
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
CA2670976C
(en)
|
2006-11-30 |
2015-01-27 |
Atsushi Hasuoka |
Cyclic amine compound
|
|
US8921326B2
(en)
*
|
2006-12-18 |
2014-12-30 |
Takeda Pharmaceutical Company Limited |
Sustained-release composition and method for producing the same
|
|
CA2696053A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases
|
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
US20080220104A1
(en)
*
|
2007-03-08 |
2008-09-11 |
Cappello John V |
Compositions for producing satiety
|
|
EP2514740B1
(en)
|
2007-03-15 |
2018-12-19 |
Auspex Pharmaceuticals, Inc. |
Deuterated o-desmethylvenlafaxines with serotoninergic and/or norepinephrinergic activity
|
|
US8673859B2
(en)
|
2007-03-20 |
2014-03-18 |
New York University |
GM-CSF cosmeceutical compositions and methods of use thereof
|
|
ES2402172T3
(es)
|
2007-04-23 |
2013-04-29 |
Intarcia Therapeutics, Inc |
Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
|
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
|
MX2010000465A
(es)
*
|
2007-07-12 |
2010-08-30 |
Tragara Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
|
|
ITSA20070024A1
(it)
*
|
2007-07-27 |
2009-01-28 |
Univ Degli Studi Salerno |
Processo continuo per la produzione di microsfere mediante liquidi espansi.
|
|
CA2699151A1
(en)
*
|
2007-09-11 |
2009-03-19 |
Activx Biosciences, Inc. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
|
|
WO2009035684A1
(en)
|
2007-09-12 |
2009-03-19 |
Activx Biosciences, Inc. |
Spirocyclic aminoquinolones as gsk-3 inhibitors
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
PT2268623E
(pt)
|
2008-03-17 |
2015-09-17 |
Ambit Biosciences Corp |
Derivados de quinazolina como moduladores de cinase raf e métodos para utilização dos mesmos
|
|
WO2009139880A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Celgene Corporation |
Thioxoisoindoline compounds and compositions and methods of using the same
|
|
CN102083466A
(zh)
*
|
2008-05-20 |
2011-06-01 |
科莱尼斯医疗公司 |
用于组合疗法的烟酸和nsaid
|
|
US8765162B2
(en)
*
|
2008-06-30 |
2014-07-01 |
Abbott Cardiovascular Systems Inc. |
Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
|
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
|
CN104248623B
(zh)
*
|
2008-09-04 |
2020-04-03 |
安米林药品有限责任公司 |
使用非水性载体的持续释放制剂
|
|
EP2376524B1
(en)
|
2008-12-31 |
2017-03-15 |
Cypralis Limited |
Derivatives of cyclosporin a
|
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
|
CN105837560A
(zh)
|
2009-02-27 |
2016-08-10 |
埃姆比特生物科学公司 |
调控jak激酶的喹唑啉衍生物和其使用方法
|
|
EP2403860B1
(en)
|
2009-03-04 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
|
|
JP5502889B2
(ja)
*
|
2009-03-11 |
2014-05-28 |
杏林製薬株式会社 |
ｇｓｋ−３阻害剤としての７−シクロアルキルアミノキノロン
|
|
JP2012520314A
(ja)
|
2009-03-11 |
2012-09-06 |
アムビト ビオスシエンセス コルポラチオン |
癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
JP5766177B2
(ja)
|
2009-03-27 |
2015-08-19 |
ベトディーシー，インコーポレイテッド |
ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
|
|
HUE025647T2
(en)
|
2009-04-22 |
2016-04-28 |
Axikin Pharmaceuticals Inc |
Arylsulfonamide CCR3 antagonists
|
|
KR101687144B1
(ko)
|
2009-04-22 |
2016-12-15 |
액시킨 파마수티컬스 인코포레이티드 |
2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
|
|
CN102459178A
(zh)
|
2009-04-22 |
2012-05-16 |
埃克希金医药品有限公司 |
2，5-二取代的芳基磺酰胺ccr3拮抗剂
|
|
US8911766B2
(en)
*
|
2009-06-26 |
2014-12-16 |
Abbott Cardiovascular Systems Inc. |
Drug delivery compositions including nanoshells for triggered drug release
|
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
|
AR080945A1
(es)
|
2009-07-07 |
2012-05-23 |
Pathway Therapeutics Inc |
Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
|
|
EP4538227A3
(en)
|
2009-07-08 |
2025-06-25 |
Hope Medical Enterprises, Inc. d.b.a. Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical compositions
|
|
WO2011009961A1
(en)
|
2009-07-24 |
2011-01-27 |
Virologik Gmbh |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
|
US9284307B2
(en)
|
2009-08-05 |
2016-03-15 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors
|
|
KR20120059558A
(ko)
|
2009-08-19 |
2012-06-08 |
암비트 바이오사이언시즈 코포레이션 |
바이아릴 화합물 및 이의 사용 방법
|
|
CA2775676C
(en)
|
2009-09-28 |
2016-08-16 |
Intarcia Therapeutics, Inc. |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
|
TW201120037A
(en)
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
WO2011075615A1
(en)
|
2009-12-18 |
2011-06-23 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
US8710092B2
(en)
*
|
2009-12-23 |
2014-04-29 |
Map Pharmaceuticals, Inc. |
Substituted indolo 4,3 FG quinolines useful for treating migraine
|
|
CA2785978A1
(en)
|
2009-12-30 |
2011-07-07 |
Scynexis, Inc. |
Cyclosporine analogues
|
|
WO2011089166A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
|
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
|
ES2632548T3
(es)
|
2010-02-05 |
2017-09-14 |
Tragara Pharmaceuticals, Inc. |
Formas de estado sólido de los inhibidores de la quinasa macrocíclica
|
|
KR101931468B1
(ko)
|
2010-02-11 |
2018-12-20 |
셀진 코포레이션 |
아릴메톡시 이소인돌린 유도체 및 그를 포함하는 조성물 및 그의 사용 방법
|
|
EP2542542B1
(en)
|
2010-03-02 |
2015-04-22 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
|
CN102892754A
(zh)
|
2010-03-17 |
2013-01-23 |
埃克希金医药品有限公司 |
芳基磺酰胺ccr3拮抗剂
|
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
|
US9296722B2
(en)
|
2010-05-27 |
2016-03-29 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
|
MX342465B
(es)
|
2010-06-01 |
2016-09-30 |
Biotheryx Inc * |
Metodos para tratar enfermedades hematologicas usando 6-ciclohexil-1-hidroxi-4-metil-2(1h)-piridona.
|
|
CN103038216A
(zh)
|
2010-06-01 |
2013-04-10 |
拜欧赛里克斯公司 |
羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
|
|
EP2576532B1
(en)
|
2010-06-07 |
2018-07-18 |
Novomedix, LLC |
Furanyl compounds and the use thereof
|
|
US9295663B2
(en)
|
2010-07-14 |
2016-03-29 |
Abbott Cardiovascular Systems Inc. |
Drug coated balloon with in-situ formed drug containing microspheres
|
|
MX347927B
(es)
|
2010-07-19 |
2017-05-19 |
Summa Health System |
Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
|
|
EP2611502A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
US20130303533A1
(en)
|
2010-09-01 |
2013-11-14 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
|
JP5872558B2
(ja)
|
2010-09-01 |
2016-03-01 |
アムビト ビオスシエンセス コルポラチオン |
ピラゾリルアミノキナゾリンの臭化水素酸塩
|
|
US20130225615A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
|
EP2611794A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
US20130317045A1
(en)
|
2010-09-01 |
2013-11-28 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
|
WO2012030912A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
|
ES2581840T3
(es)
|
2010-09-01 |
2016-09-07 |
Ambit Biosciences Corporation |
Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma
|
|
EP2663553B1
(en)
|
2010-09-01 |
2015-08-26 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
|
MX2013002384A
(es)
|
2010-09-01 |
2013-07-05 |
Ambit Biosciences Corp |
Compuestos quinazolina y metodos para utilizarlos.
|
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
EP2627635A1
(en)
|
2010-10-11 |
2013-08-21 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
|
JP2013545749A
(ja)
|
2010-11-10 |
2013-12-26 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
複素環化合物及びその使用
|
|
JP2014500275A
(ja)
|
2010-12-06 |
2014-01-09 |
フォリカ，インコーポレイテッド |
禿頭症を治療するため、および毛髪の成長を促進するための方法
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
KR101411349B1
(ko)
|
2010-12-24 |
2014-06-25 |
주식회사 삼양바이오팜 |
생리활성 펩타이드를 포함하는 마이크로입자 및 그의 제조방법, 및 그를 포함하는 약제학적 조성물
|
|
NZ612909A
(en)
|
2011-01-10 |
2015-09-25 |
Infinity Pharmaceuticals Inc |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
|
CA2825152A1
(en)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
EP2683384B1
(en)
|
2011-03-11 |
2015-12-09 |
Celgene Corporation |
Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
|
|
CA2831590A1
(en)
|
2011-03-28 |
2012-10-04 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
EP2691388A1
(en)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
WO2012135160A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
WO2012154321A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
MX2013015373A
(es)
|
2011-06-23 |
2014-02-11 |
Map Pharmaceuticals Inc |
Nuevos analogos de fluoroergolina.
|
|
JP6027611B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
複素環式化合物及びその使用
|
|
HK1198443A1
(en)
|
2011-07-19 |
2015-04-24 |
无限药品股份有限公司 |
Heterocyclic compounds and uses thereof
|
|
WO2013032591A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
CN103906759A
(zh)
|
2011-09-12 |
2014-07-02 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
|
TW201329096A
(zh)
|
2011-09-12 |
2013-07-16 |
Idenix Pharmaceuticals Inc |
經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
|
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
|
EP2768838A1
(en)
|
2011-10-14 |
2014-08-27 |
IDENIX Pharmaceuticals, Inc. |
Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
|
RS54936B1
(sr)
|
2011-10-14 |
2016-11-30 |
Ambit Biosciences Corp |
Heterociklična jedinjenja i njihova upotreba kao modulatora receptora tirozin kinaza tipa iii
|
|
WO2013095707A1
(en)
|
2011-12-19 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
|
AU2012355983A1
(en)
|
2011-12-21 |
2015-01-22 |
Map Pharmaceuticals, Inc. |
Novel neuromodulatory compounds
|
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
|
WO2013138613A1
(en)
|
2012-03-16 |
2013-09-19 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
|
EP2852604B1
(en)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
CN104470939B
(zh)
|
2012-05-22 |
2017-04-26 |
埃迪尼克斯医药有限责任公司 |
用于肝脏疾病的d型氨基酸化合物
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
EP2873455B1
(en)
|
2012-07-12 |
2021-07-07 |
Takeda Pharmaceutical Company Limited |
Method for manufacturing microcapsule powder
|
|
UA114521C2
(uk)
|
2012-08-09 |
2017-06-26 |
Селджин Корпорейшн |
Солі і тверді форми (s)-3-(4-((4-морфолінометил)-бензил)оксі)-1-оксоізоіндолін-2-іл)-піперидин-2,6-діону і композиції, які їх включають, і способи їхнього застосування
|
|
CN108938642A
(zh)
|
2012-08-09 |
2018-12-07 |
细胞基因公司 |
免疫相关和炎性疾病的治疗
|
|
CA2922849A1
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
|
EP2892884A1
(en)
|
2012-09-07 |
2015-07-15 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
EP2906579B1
(en)
|
2012-10-08 |
2018-04-18 |
Idenix Pharmaceuticals LLC. |
2'-chloro nucleoside analogs for hcv infection
|
|
EP2909223B1
(en)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinucleotide compounds for hcv infection
|
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
|
SMT201800561T1
(it)
|
2012-11-01 |
2018-11-09 |
Infinity Pharmaceuticals Inc |
Trattamento di cancri usando modulatori di isoforme di pi3 chinasi
|
|
WO2014074765A2
(en)
|
2012-11-08 |
2014-05-15 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
|
US20140140952A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Sp-Nucleoside Analog
|
|
CN104955801B
(zh)
|
2012-11-30 |
2017-10-31 |
诺沃梅迪科斯有限公司 |
取代的二芳基磺酰胺及其用途
|
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
CA2895829A1
(en)
|
2012-12-21 |
2014-06-26 |
Map Pharmaceuticals, Inc. |
Novel methysergide derivatives
|
|
WO2014110305A1
(en)
|
2013-01-11 |
2014-07-17 |
Mayo Foundation For Medical Education And Research |
Vitamins c and k for treating polycystic diseases
|
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
ES2834638T3
(es)
|
2013-05-30 |
2021-06-18 |
Infinity Pharmaceuticals Inc |
Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa
|
|
WO2014197578A1
(en)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucleosides for the treatment of hcv
|
|
EP3027636B1
(en)
|
2013-08-01 |
2022-01-05 |
Idenix Pharmaceuticals LLC |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
HK1225718A1
(zh)
|
2013-08-30 |
2017-09-15 |
Ambit Biosciences Corporation |
联芳基乙酰胺化合物及其使用方法
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
US20160229866A1
(en)
|
2013-09-20 |
2016-08-11 |
Idenix Pharmaceuticals Inc. |
Hepatitis c virus inhibitors
|
|
WO2015051336A1
(en)
|
2013-10-03 |
2015-04-09 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US9359365B2
(en)
|
2013-10-04 |
2016-06-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
|
CN104587534A
(zh)
*
|
2013-10-31 |
2015-05-06 |
先健科技(深圳)有限公司 |
可吸收铁基合金支架
|
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
|
US10030044B2
(en)
|
2013-11-27 |
2018-07-24 |
Idenix Pharmaceuticals Llc |
Nucleotides for the treatment of liver cancer
|
|
WO2015081297A1
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
|
WO2015095419A1
(en)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
4'-or nucleosides for the treatment of hcv
|
|
EP3114122A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
JP6701088B2
(ja)
|
2014-03-19 |
2020-05-27 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
|
|
KR102409739B1
(ko)
|
2014-03-20 |
2022-06-17 |
카펠라 테라퓨틱스, 인크. |
암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
|
|
DK3119762T3
(da)
|
2014-03-20 |
2021-08-30 |
Capella Therapeutics Inc |
Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
|
|
US10106549B2
(en)
|
2014-04-09 |
2018-10-23 |
Siteone Therapeutics, Inc. |
10′,11′-modified saxitoxins useful for the treatment of pain
|
|
WO2015158823A1
(de)
|
2014-04-16 |
2015-10-22 |
Veyx-Pharma Gmbh |
Veterinärpharmazeutische zusammensetzung und deren verwendung
|
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
|
WO2015175381A1
(en)
|
2014-05-12 |
2015-11-19 |
Conatus Pharmaceuticals, Inc. |
Treatment of the complications of chronic liver disease with caspase inhibitors
|
|
KR20170005492A
(ko)
|
2014-05-28 |
2017-01-13 |
아이데닉스 파마슈티칼스 엘엘씨 |
암의 치료를 위한 뉴클레오시드 유도체
|
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
|
PT3157916T
(pt)
|
2014-06-19 |
2019-03-25 |
Ariad Pharma Inc |
Compostos heteroarilo para inibição de cinase
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
TW201618783A
(zh)
|
2014-08-07 |
2016-06-01 |
艾森塔製藥公司 |
以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
|
|
KR20170066418A
(ko)
|
2014-09-12 |
2017-06-14 |
토비라 쎄라퓨틱스, 인크. |
섬유증의 치료를 위한 세니크리비록 병용 요법
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
|
CA2965169C
(en)
|
2014-10-21 |
2021-11-16 |
Ariad Pharmaceuticals, Inc. |
Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine
|
|
US20170354639A1
(en)
|
2014-10-24 |
2017-12-14 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
AR103264A1
(es)
|
2014-12-23 |
2017-04-26 |
Axikin Pharmaceuticals Inc |
Derivados de 3,5-aminopirazol como inhibidores de quinasa rc
|
|
CN107405346A
(zh)
|
2015-01-20 |
2017-11-28 |
Xoc制药股份有限公司 |
异麦角灵化合物及其用途
|
|
MX2017009405A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo ergolina y usos de estos.
|
|
EP3303361A1
(en)
|
2015-05-27 |
2018-04-11 |
Idenix Pharmaceuticals LLC |
Nucleotides for the treatment of cancer
|
|
CN107920884B
(zh)
|
2015-06-03 |
2021-08-27 |
因塔西亚制药公司 |
植入物放置和移除系统
|
|
CN113713108A
(zh)
|
2015-06-23 |
2021-11-30 |
纽罗克里生物科学有限公司 |
用于治疗神经学疾病或病症的vmat2抑制剂
|
|
AU2016308564B2
(en)
|
2015-08-17 |
2018-04-26 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyl transferase inhibitors
|
|
EP4585268A3
(en)
|
2015-09-14 |
2025-10-15 |
Twelve Therapeutics, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
CA3000708A1
(en)
|
2015-09-30 |
2017-04-06 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
EP3875459B1
(en)
|
2015-10-30 |
2023-12-13 |
Neurocrine Biosciences, Inc. |
Valbenazine dihydrochloride salts and polymorphs thereof
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
WO2017096323A1
(en)
|
2015-12-02 |
2017-06-08 |
Astraea Therapeutics, Llc |
Piperidinyl nociceptin receptor compounds
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
HRP20220621T1
(hr)
|
2015-12-23 |
2022-06-24 |
Neurocrine Biosciences, Inc. |
Postupak sinteze za proizvodnju (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
|
|
BR112018013558A2
(pt)
|
2015-12-31 |
2018-12-04 |
Conatus Pharmaceuticals Inc |
método de tratamento de uma doença hepática em um indivíduo, método de uso de um inibidor de caspase, método para diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação de child-pugh ou seus componentes, composição farmacêutica que compreende um inibidor de caspase, kit, método de tratamento, método de tratamento de cirrose hepática e prevenção de uma classificação meld elevada, método de tratamento de cirrose hepática e prevenção de uma classificação de child-pugh elevada
|
|
CN108430473B
(zh)
|
2016-01-08 |
2021-08-31 |
细胞基因公司 |
抗增殖化合物以及其药物组合物和用途
|
|
TWI733734B
(zh)
|
2016-01-08 |
2021-07-21 |
美商西建公司 |
2-(4-氯苯基)-n-((2-(2,6-二氧六氫吡啶-3-基)-1-氧基異吲哚啉-5-基)甲基)-2,2-二氟乙醯胺之固體型式，及其醫藥組合物及用途
|
|
AU2017205170B2
(en)
|
2016-01-08 |
2021-06-24 |
Celgene Corporation |
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
|
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
|
EP3442940A1
(en)
|
2016-04-11 |
2019-02-20 |
Clexio Biosciences Ltd. |
Deuterated ketamine derivatives
|
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
JP6931695B2
(ja)
|
2016-04-29 |
2021-09-08 |
エフジーエイチ バイオテック，インコーポレーテッド |
疾患の治療のための二置換ピラゾール化合物
|
|
EP3458084B1
(en)
|
2016-05-16 |
2020-04-01 |
Intarcia Therapeutics, Inc |
Glucagon-receptor selective polypeptides and methods of use thereof
|
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3510027B1
(en)
|
2016-09-07 |
2022-11-02 |
FGH BioTech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
|
KR20190058550A
(ko)
|
2016-09-19 |
2019-05-29 |
메이 파마, 아이엔씨. |
병용 요법
|
|
SG11201903786UA
(en)
|
2016-11-03 |
2019-05-30 |
Kura Oncology Inc |
Farnesyltransferase inhibitors for use in methods of treating cancer
|
|
CA3042055A1
(en)
|
2016-11-09 |
2018-05-17 |
Novomedix, Llc |
Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
JP7105774B2
(ja)
|
2016-12-01 |
2022-07-25 |
イグナイタ インコーポレイテッド |
がん治療のための方法
|
|
TW202515564A
(zh)
|
2016-12-02 |
2025-04-16 |
美商紐羅克里生物科學有限公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
US10835580B2
(en)
|
2017-01-03 |
2020-11-17 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
|
PH12022553251A1
(en)
|
2017-01-27 |
2024-05-20 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
JP7289795B2
(ja)
|
2017-02-21 |
2023-06-12 |
クラ オンコロジー， インコーポレイテッド |
ファルネシルトランスフェラーゼ阻害剤を用いてがんを治療する方法
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
|
KR20190127699A
(ko)
|
2017-03-27 |
2019-11-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조성물 및 방법
|
|
CA3058214A1
(en)
|
2017-03-29 |
2018-10-04 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
US11279706B2
(en)
|
2017-03-29 |
2022-03-22 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
PL3624796T3
(pl)
|
2017-05-19 |
2025-06-30 |
Nflection Therapeutics, Inc. |
Związki pirolopirydyno-anilinowe do leczenia zaburzeń skórnych
|
|
DK3624795T3
(da)
|
2017-05-19 |
2022-05-23 |
Nflection Therapeutics Inc |
Kondenserede, heteroaromatiske anilinforbindelser til behandling af hudforstyrrelser
|
|
AU2018275873A1
(en)
|
2017-06-01 |
2019-12-19 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
|
SG11202000894TA
(en)
|
2017-08-07 |
2020-02-27 |
Kura Oncology Inc |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
HRP20250561T1
(hr)
|
2017-09-21 |
2025-07-04 |
Neurocrine Biosciences, Inc. |
Formulacija valbenazina visoke doze i pripravci, postupci i pribor povezani s njima
|
|
SG11202002687UA
(en)
|
2017-10-04 |
2020-04-29 |
Univ California |
Immunomodulatory oligosaccharides
|
|
CN116492340A
(zh)
|
2017-10-10 |
2023-07-28 |
纽罗克里生物科学有限公司 |
施用某些vmat2抑制剂的方法
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
WO2019139869A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
|
MX2020013004A
(es)
|
2018-06-14 |
2021-02-17 |
Neurocrine Biosciences Inc |
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
|
|
US11447497B2
(en)
|
2018-06-29 |
2022-09-20 |
Histogen, Inc. |
(S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
SG11202100303QA
(en)
|
2018-08-15 |
2021-02-25 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2020072835A1
(en)
|
2018-10-03 |
2020-04-09 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
AU2019372141A1
(en)
|
2018-11-01 |
2021-05-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
CN113473986B
(zh)
|
2018-11-20 |
2024-10-11 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病萘啶酮苯胺化合物
|
|
CA3120336A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
|
|
US20220087989A1
(en)
|
2018-11-20 |
2022-03-24 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
|
MA55141A
(fr)
|
2018-11-20 |
2021-09-29 |
Nflection Therapeutics Inc |
Composés cyanoaryl-aniline pour le traitement d'affections de la peau
|
|
EP3898609A1
(en)
|
2018-12-19 |
2021-10-27 |
Shy Therapeutics LLC |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
|
CA3124616A1
(en)
|
2018-12-21 |
2020-06-25 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
|
US11447468B2
(en)
|
2019-02-06 |
2022-09-20 |
Dice Alpha, Inc. |
IL-17 ligands and uses thereof
|
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
JP7645192B2
(ja)
|
2019-03-07 |
2025-03-13 |
ノボ メディシン インク． |
カスパーゼ阻害剤及びその使用方法
|
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
EP3946338B1
(en)
|
2019-03-29 |
2025-06-18 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
US20220168296A1
(en)
|
2019-04-01 |
2022-06-02 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
EP3997068A1
(en)
|
2019-07-11 |
2022-05-18 |
Cura Therapeutics, LLC |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
|
WO2021007474A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
|
CN114126593B
(zh)
|
2019-07-26 |
2024-07-26 |
埃斯佩尔维塔治疗股份有限公司 |
可用于预防或治疗疾病的官能化的长链烃一元和二元羧酸
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
BR112022004802A2
(pt)
|
2019-09-16 |
2022-08-23 |
Dice Alpha Inc |
Moduladores de il-17a e usos dos mesmos
|
|
EP4034236A1
(en)
|
2019-09-26 |
2022-08-03 |
Abionyx Pharma SA |
Compounds useful for treating liver diseases
|
|
TW202126631A
(zh)
|
2019-10-01 |
2021-07-16 |
美商分子皮膚療法公司 |
作為klk5/7雙重抑制劑之苯并酮化合物
|
|
WO2021242970A1
(en)
|
2020-05-29 |
2021-12-02 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
|
WO2021257828A1
(en)
|
2020-06-18 |
2021-12-23 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
JP2023532312A
(ja)
|
2020-06-30 |
2023-07-27 |
プロセッタ バイオサイエンシズ， インク． |
イソキノリン誘導体、合成の方法及びそれらの使用
|
|
BR112023002659A2
(pt)
|
2020-08-14 |
2023-05-02 |
Siteone Therapeutics Inc |
Inibidores de cetona não hidratados de nav1.7 para o tratamento da dor
|
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
|
WO2022192545A1
(en)
|
2021-03-10 |
2022-09-15 |
Dice Molecules Sv, Inc. |
Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
|
|
EP4319790A4
(en)
*
|
2021-04-08 |
2025-02-26 |
Enteris BioPharma, Inc. |
METHODS OF TREATING PEDIATRIC PUBERTY USING ORAL FORMULATIONS OF LEUPROLIDE
|
|
EP4326721A1
(en)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
EP4347568A1
(en)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
US12017997B2
(en)
|
2021-10-22 |
2024-06-25 |
Prosetta Biosciences, Inc. |
Host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
TW202327590A
(zh)
|
2021-11-30 |
2023-07-16 |
美商庫拉腫瘤技術股份有限公司 |
大環化合物及組合物以及其製備及使用方法
|
|
US11981694B2
(en)
|
2022-01-03 |
2024-05-14 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
CN118922189A
(zh)
|
2022-03-02 |
2024-11-08 |
线粒体能量有限公司 |
衍生自烟酸和核糖的新型前药
|
|
AU2023241822A1
(en)
|
2022-03-28 |
2024-09-26 |
Isosterix, Inc. |
Inhibitors of the myst family of lysine acetyl transferases
|
|
AU2023245901A1
(en)
|
2022-03-30 |
2024-10-03 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
CN119013266A
(zh)
|
2022-04-14 |
2024-11-22 |
百时美施贵宝公司 |
新颖gspt1化合物以及新颖化合物的使用方法
|
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
|
EP4514789A1
(en)
|
2022-04-25 |
2025-03-05 |
SiteOne Therapeutics, Inc. |
<sup2/>? <sub2/>?v?bicyclic heterocyclic amide inhibitors of na1.8 for the treatment of pain
|
|
US20230416741A1
(en)
|
2022-05-05 |
2023-12-28 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
|
AU2023338217A1
(en)
|
2022-09-09 |
2025-04-03 |
Innovo Therapeutics, Inc. |
CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
|
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
|
EP4605084A2
(en)
|
2022-10-18 |
2025-08-27 |
Eluciderm Inc. |
2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- d]pyrimidin-4-ones for wound treatment
|
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
|
EP4608838A1
(en)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
EP4626864A1
(en)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
EP4626865A1
(en)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
WO2024145662A1
(en)
|
2022-12-30 |
2024-07-04 |
Altay Therapeutics, Inc. |
2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
|
|
WO2024226471A2
(en)
|
2023-04-24 |
2024-10-31 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating stxbp1 disorders
|
|
TW202448485A
(zh)
|
2023-05-05 |
2024-12-16 |
美商拜奧馬林製藥公司 |
肌萎縮蛋白外顯子跳躍寡核苷酸
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
WO2025072489A2
(en)
|
2023-09-27 |
2025-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
|
|
US20250122182A1
(en)
|
2023-09-27 |
2025-04-17 |
Isosterix, Inc. |
MYST Inhibitors
|
|
WO2025085416A1
(en)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
WO2025085878A1
(en)
|
2023-10-20 |
2025-04-24 |
Altay Therapeutics, Inc. |
N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders
|
|
WO2025102082A1
(en)
|
2023-11-10 |
2025-05-15 |
Altay Therapeutics, Inc. |
Carbocyclic and heterocyclic stat3 inhibitor compositions and methods
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025147691A1
(en)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
WO2025160286A1
(en)
|
2024-01-24 |
2025-07-31 |
Siteone Therapeutics, Inc. |
2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025221809A1
(en)
|
2024-04-16 |
2025-10-23 |
Eluciderm Inc. |
2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases
|
|
WO2025240895A1
(en)
|
2024-05-17 |
2025-11-20 |
Siteone Therapeutics, Inc. |
SUBSTITUTED CYCLOALKYL AND HETEROCYCLOALKYL INHIBITORS OF NAv1.8 FOR THE TREATMENT OF PAIN
|